Summary:
Etopozide, a podophyllotoxin derivative, has demonstrated antitumour efficacy in a number of human malignancies, particularly in malignant lymphomas. Etoposide's antineoplastic activity is achieved through DNA breakage, which results from the inhibition of enzyme topoisomerase II. It has been used in a wide variety of treatment settings (induction regimens, salvage therapy). The importance of schedule in the cytotoxic efficacy of etoposlde is discussed. Increasing evidence suggests that chronic schedules of oral etoposlde have increased efficacy when compared with the standard i. v. dose and schedules.
The contemporary applying of etoposlde in the treatment of malignant lymphomas
